美國居民不適用 XM 服務。
A
A

Agilent


財經新聞

U.S. Advance Auto Parts, Chewy, Workday

U.S. RESEARCH ROUNDUP-Advance Auto Parts, Chewy, Workday Aug 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Advance Auto Parts, Chewy and Workday, on Friday. HIGHLIGHTS * Advance Auto Parts Inc AAP.N : JP Morgan cuts target price to $43 from $55 * Chewy CHWY.N : Piper Sandler raises to overweight from neutral * Intuit Inc INTU.O : Jefferies raises target price to $790 from $770 * Williams-Sonoma Inc WSM.N : TD Co
A
A
A
B
I
J
N
N
R
R
H
A

U.S. STOCKS NetEase, Wolfspeed, B. Riley

BUZZ-U.S. STOCKS ON THE MOVE-NetEase, Wolfspeed, B. Riley Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in volatile trading on Thursday, as rising Treasury yields pressured stocks ahead of Federal Reserve Chair Jerome Powell's speech at Jackson Hole that could offer clues on the possibility of a rate cut next month.
A
B
N
S
U
U
U
E
S
A

U.S. STOCKS Evogene, Stryker, Opera

BUZZ-U.S. STOCKS ON THE MOVE-Evogene, Stryker, Opera Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell in volatile trading on Thursday, as rising Treasury yields pressured stocks ahead of Federal Reserve Chair Jerome Powell's speech at Jackson Hole that could offer clues on the possibility of a rate cut next month.
A
B
B
I
N
U
U
U
E
S
A

Agilent Technologies rises on Q3 results beat

BUZZ-Agilent Technologies rises on Q3 results beat ** Shares of medical equipment maker Agilent Technologies A.N rise 3.6% to $145.03 after Q3 results ** Company reports Q3 revenue of $1.58 bln; above Wall Street expectations of $1.56 bln - LSEG data ** Quarterly adj EPS of $1.32 beat market estimate of $1.26 ** Co forecasts Q4 revenue between $1.6
A

U.S. Aadi Bioscience, Target, Visteon

U.S. RESEARCH ROUNDUP-Aadi Bioscience, Target, Visteon Aug 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aadi Bioscience, Target and Visteon, on Thursday. HIGHLIGHTS * Aadi Bioscience Inc AADI.O : Jefferies cuts to hold from buy * Assurant Inc AIZ.N : Piper Sandler cuts to neutral from overweight * Estée Lauder EL.N : Piper Sandler raises to overweight from neutral * Target Corp TGT.N : Jefferies raises target
A
A
H
S
T
T
U
A
P
U
D
E
A

Agilent Technologies Inc reports results for the quarter ended in July - Earnings Summary

Agilent Technologies Inc reports results for the quarter ended in July - Earnings Summary Agilent Technologies Inc A.N reported quarterly adjusted earnings of $1.32​​ per share for the quarter ended in July, lower than the same quarter last year, when the company reported EPS of $1.43. The mean expectation of seventeen analysts for the quarter was for earnings of $1.26 per share.
A

Agilent beats quarterly results on strong demand from biotech clients

Agilent beats quarterly results on strong demand from biotech clients Aug 21 (Reuters) - Agilent Technologies A.N on Wednesday beat Wall Street estimates for third-quarter profit and revenue, banking on strong demand for its medical tools and equipment used in clinical studies. "While market conditions continued to be challenged during the quarter, we saw steady signs of improvement as anticipated", said CEO Padraig McDonnell.
A
T

Agilent Q3 Revenue USD 1,578 Million Vs. IBES Estimate USD 1,558 Million

BRIEF-Agilent Q3 Revenue USD 1,578 Million Vs. IBES Estimate USD 1,558 Million Aug 21 (Reuters) - Agilent Q3 income from operations USD 333 million. Q3 net income USD 282 million Q3 pretax profit USD 343 million vs. IBES estimate USD 428.4 million Q3 EPS USD 0.97 Q3 adjusted net income USD 385 million vs. IBES estimate USD 371 million Q3 adjusted EPS USD 1.32 vs.
A

Agilent Technologies Inc <A.N> expected to post earnings of $1.26 a share - Earnings Preview

Agilent Technologies Inc expected to post earnings of $1.26 a share - Earnings Preview Agilent Technologies Inc A.N , A is expected to show a fall in quarterly revenue when it reports results on August 21 for the period ending January 1 0001 The Santa Clara California-based company is expected to report a 6.8% decrease in revenue to $1.558 billion from $1.67 billion a year ago, according to the mean estimate from 14 analysts, based on LSEG data.The company's guidance on May 29 2024, for the peri
A

U.S. earnings week ahead

DIARY-U.S. earnings week ahead Aug 16 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 19-Aug-2024 AMC PANW.O Palo Alto Networks Inc Q4 2024 Palo Alto Networks Inc Earnings Release 19-Aug-2024 BMO EL Estee Lauder Companies Inc Q4 2024 Estee Lauder Companies Inc Earnings Release 20-Aug-2024 AMC KEYS Keysight Technologies Inc Q3 2024 Key
A
I
A
R
U
E
K

Waters Corp climbs after Q2 results beat

BUZZ-Waters Corp climbs after Q2 results beat Updates ** Shares of lab equipment maker Waters Corp WAT.N rise ~4.1% to $341.09, their highest since May ** WAT reports Q2 adj. profit of $2.63/shr vs analysts' average estimate of $2.56/shr - LSEG data ** Posts quarterly revenue of $708.5 mln vs analysts' expectation of $700.1 mln ** Company forecasts annual adj.
A
W

Waters Corp falls on annual profit forecast cut

BUZZ-Waters Corp falls on annual profit forecast cut ** Shares of lab equipment maker Waters Corp WAT.N fall ~2.3% to $320.01 premarket ** Co forecasts annual adj. profit between $11.55 and $11.65 per share below previous forecast of $11.75-$12.05 ** Evercore analyst Vijay Kumar says WAT's forecast cut was "generally expected" given peer Agilent's A.N revenue forecast cut in May ** WAT reports Q2 adj.
A
W

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Mattel, Tellurian Updates: Clearwater Paper, Agilent July 22 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1955 GMT on Monday: * * L Catterton, the private equity firm backed by luxury goods giant LVMH LVMH.PA , has approached Mattel MAT.O , the toy maker behind Barbie and Hot Wheels, with an acquisition offer, people familiar with the matter said.
A
G
H
L
M
V
D

Agilent Technologies To Acquire BIOVECTRA for $925 Million

BRIEF-Agilent Technologies To Acquire BIOVECTRA for $925 Million July 22 (Reuters) - Agilent Technologies Inc A.N : AGILENT TO ACQUIRE NORTH AMERICAN CDMO BIOVECTRA AGILENT TECHNOLOGIES INC - TO ACQUIRE BIOVECTRA FOR $925 MILLION AGILENT TECHNOLOGIES INC - EXPECTS ACQUISITION TO BE $0.05 DILUTIVE TO NON-GAAP EPS Source text for Eikon: ID:nBw5TcW1Fa
A

Agilent to buy contract drug manufacturer Biovectra for $925 mln

UPDATE 2-Agilent to buy contract drug manufacturer Biovectra for $925 mln Adds deal details in paragraph 5 and background throughout July 22 (Reuters) - Agilent Technologies A.N said on Monday it will acquire contract drug manufacturer Biovectra for $925 million to expand its portfolio of services offered to biotech companies and medical researchers.
A

Agilent to buy contract drug manufacturer Biovectra for $925 million

Agilent to buy contract drug manufacturer Biovectra for $925 million July 22 (Reuters) - Medical equipment maker Agilent Technologies A.N said on Monday it will acquire privately held contract drug manufacturer Biovectra for $925 million. Reporting by Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta
A

U.S. Elevance Health, J&J, Primerica

U.S. RESEARCH ROUNDUP-Elevance Health, J&J, Primerica July 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Elevance Health, J&J and Primerica, on Thursday. HIGHLIGHTS * Elevance Health Inc ELV.N : Leerink Partners cuts target price to $620 from $630 * J&J JNJ.N : TD Cowen cuts target price to $185 from $195 * Primerica Inc PRI.N : Jefferies raises target price to $249 from $239 * Travelers Companies Inc TRV.N : HS
A
A
O
P
Q
A
A
C

U.S. Nvidia, Qualcomm, Tesla

U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla July 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Nvidia, Qualcomm and Tesla, on Wednesday. HIGHLIGHTS * Brighthouse Financial Inc BHF.O : Jefferies raises to buy from hold * Legalzoom.Com Inc LZ.O : JP Morgan cuts to neutral from overweight * Nvidia Corp NVDA.O : KeyBanc raises target price to $180 * Qualcomm Inc QCOM.O : KeyBanc raises target price to $225 * Tesla
A
A
A
A
A
C
G
M
M
N
P
Q
S
T
A
A
A
C
O
B
T
A
A
A
A
C
G
L
U

Masimo COO Muhsin to resign if activist investor Politan takes control

UPDATE 2-Masimo COO Muhsin to resign if activist investor Politan takes control Adds background throughout July 1 (Reuters) - Masimo MASI.O Chief Operating Officer Bilal Muhsin has told the board he would resign if activist investor Politan Capital Management takes control of the company and CEO Joe Kiani is removed, according to a regulatory filing.
A
S

U.S. Alimera Sciences, Comtech Telecommunications, Eli Lilly

U.S. RESEARCH ROUNDUP-Alimera Sciences, Comtech Telecommunications, Eli Lilly June 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alimera Sciences, Comtech Telecommunications and Eli Lilly, on Tuesday. HIGHLIGHTS * Alimera Sciences Inc ALIM.O : Craig-Hallum cuts to hold from buy * Comtech Telecommunications Corp CMTL.O : Jefferies raises to hold from underperform * Eli Lilly LLY.N : Truist Securities raises targe
A
A
E
D
U
V
A
B
C
C
C
F
M



細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明